CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Certain bonds and fund structures minimize tax impact, making them attractive for retirees seeking reliable after-tax income.
22,683 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Despite a modest headline fee, the SPDR S&P Semiconductor ETF trails cheaper rivals on longer horizons, signaling a h...
As data centers expand and AI workloads surge, the tech industry faces a critical power reliability challenge. This a...
Colorado regulators announced a settlement with Unlock Technologies to reclassify home equity agreements as consumer ...
A senior tech market analyst argues that AI-driven data center investments are already generating value through pre-s...
The memory market has two giants, yet the stock gap between them has persisted. This article explores whether a Nasda...
A Monday surge put Archer Aviation stock in the spotlight as investors reacted to major eVTOL news. This guide breaks...
Federal Reserve minutes signal potential rate hikes if inflation stays elevated, shaking a crypto market that had pri...
A major biotech investor is stepping up its bet on Krystal Biotech as the company posts robust 2025 revenue. This mov...
Institutional buyers are flocking to STRC, Strategy’s variable-rate perpetual preferred stock, driving an 11% yield a...
As March moves unfold, the stock market today is colored by big auto headlines. Ford’s recall news sent ripples throu...
QuantumScape's solid-state battery efforts could redefine EV charging. This guide digs into what might drive QS stock...